Insight

Bettina Ryll: Valerie Diane Valeriano at MPNE Hubs 2024 on how the microbiome modulates response to immune therapies in Melanoma

Valerie Diane Valeriano and Bettina Ryll

Dec 9, 2024, 14:45

Bettina Ryll: Valerie Diane Valeriano at MPNE Hubs 2024 on how the microbiome modulates response to immune therapies in Melanoma

Bettina Ryll, Founder of MPN Europe, shared on LinkedIn:

“Listening to Valerie Diane Valeriano at MPNEhubs 2024 on how the microbiome modulates response to immune therapies in Melanoma and her work in the OncoBiome project.

A lot of considerations to turn an observation into something that could become a treatment a scale- and why designer microbiome consortia might be a good concept.

If you want to meet someone passionate about microbiota- you have to meet Valerie Diane Valeriano.”

Bettina Ryll

Article 1: Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

Bettina Ryll

Article 2: Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma

Bettina Ryll

More posts featuring Bettina Ryll.

anti-PD-1 therapy Bettina Ryll cancer Fecal microbiota Genomic heterogeneity Melanoma melanoma patients metastatic melanoma microbiome microbiota MPNEhubs OncoDaily Oncology patients ploidy identify Valerie Diane Valeriano

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Special Coverage